LAVA Therapeutics NV Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenue from contracts with customers
Cost of sales of goods
Cost of providing services
Gross profit
Research and development
General and administrative
Total operating expenses
Interest income (expense), net
Foreign currency exchange (loss) gain, net
Total non-operating income
Loss before income tax
Income tax expense
Loss for the year
Foreign currency translation adjustment
Total comprehensive loss
Loss per share, basic
Weighted average common shares outstanding, basic
Revenue:
Total revenue
Cost and expenses:
Cost of revenue
Research and development
General and administrative
Total cost and expenses
Operating loss
Other income (expense), net
Interest income
Interest expense
Foreign currency exchange gain (loss), net
Total other income (expense), net
Net loss before taxes
Income tax expense, net
Net loss
Other comprehensive (expense) income:
Foreign currency translation adjustment
Comprehensive loss
Net loss per share, basic
Net loss per share, diluted
Weighted-average common shares outstanding, basic
Weighted-average common shares outstanding, diluted

Comments